Core Insights - The "High Income DIY Portfolios" service aims to provide high income with low risk and capital preservation for DIY investors, particularly targeting income investors such as retirees [1][2] - The service offers a total of 10 model portfolios, including various strategies like buy-and-hold and rotational portfolios, designed to create stable, long-term passive income with sustainable yields [1][2] Group 1: Portfolio Strategies - The service includes seven portfolios: three buy-and-hold, three rotational, and a conservative NPP strategy portfolio, focusing on low drawdowns and high growth [1] - The portfolios are categorized into two High-Income portfolios, two Dividend Growth Investing (DGI) portfolios, and a conservative NPP strategy [1] Group 2: Investment Approach - The investment approach emphasizes a unique 3-basket strategy that targets 30% lower drawdowns and aims for a 6% current income with market-beating growth over the long term [2] - The service provides buy and sell alerts, as well as live chat for real-time support and guidance [2]

Core Viewpoint - The healthcare sector presents affordable investment opportunities despite broader market performance, with AbbVie and Merck identified as attractive stocks for 2026 [1][2]. AbbVie - AbbVie has diversified its product lineup following the loss of patent exclusivity for Humira in 2023, reducing dependency on a single product for sales growth [4][5]. - The company is now less risky, with no major patent cliffs until at least 2030, allowing for strategic planning and growth [6]. - AbbVie is focusing on expanding into oncology with pipeline candidates like ABBV-969 for metastatic prostate cancer and ABBV-514 for lung and neck cancers [7]. - The company is also entering the weight loss market through a licensing deal for GUB014295, which could enhance its revenue and earnings over the next five years [8]. - AbbVie is recognized as a Dividend King, having increased its dividends annually for over 50 years, indicating strong business resilience [10].

Core Insights - AbbVie's stock has recently slipped below its 50-day simple moving average (SMA), indicating recent selling pressure, despite a recovery after a post-earnings dip [1][2][8] - The company has successfully launched new drugs, Skyrizi and Rinvoq, which are expected to drive revenue growth in the coming years, offsetting declines from Humira and the Aesthetics unit [5][7][29] Financial Performance - AbbVie reported combined sales of Skyrizi and Rinvoq at $18.5 billion for the first nine months of 2025, with expectations to exceed $25 billion in 2025 and $31 billion by 2027 [6][7] - The oncology segment generated revenues of $5.0 billion in the first nine months of 2025, a 2.7% year-over-year increase, driven by new drug sales [10] - Neuroscience drug sales increased by 20.3% to nearly $7.8 billion in the same period, supported by products like Botox Therapeutic and Vraylar [11] Market Challenges - Humira's sales have declined over 50% in the first nine months of 2025 due to biosimilar erosion, significantly impacting overall revenue [15] - The Aesthetics segment has seen a 7.4% decline in global sales, with Juvederm and Botox Cosmetics sales falling by 16.7% and 7.4%, respectively [16][17] Strategic Initiatives - AbbVie has been actively pursuing acquisitions to enhance its early-stage pipeline, completing over 30 M&A transactions since early 2024 [14] - The company recently settled patent litigation for Rinvoq, extending its patent exclusivity to 2037, which is expected to bolster its revenue stream [9] Future Outlook - AbbVie anticipates returning to mid-single-digit revenue growth in 2025, driven by strong performances from Skyrizi and Rinvoq, with a high single-digit CAGR projected through 2029 [29] - The company has increased its quarterly cash dividend by 5.5%, reflecting confidence in future growth despite recent estimate declines [30]

Group 1: McDonald's Corporation - McDonald's continues to show strong performance with a notable increase in global comparable sales, which rose by 10.3% in the last quarter [1] - The company is focusing on digital innovation and menu enhancements to drive customer engagement and sales growth [1] - McDonald's expansion strategy includes opening new locations in international markets, contributing to overall revenue growth [1] Group 2: Walmart Inc - Walmart reported a 6.2% increase in total revenue, reaching $152.9 billion for the last quarter, driven by strong e-commerce sales [1] - The company is investing heavily in technology to improve supply chain efficiency and enhance customer experience [1] - Walmart's grocery segment remains a key growth driver, with a significant increase in online grocery orders [1] Group 3: AbbVie Inc - AbbVie experienced a revenue increase of 8.5%, totaling $14.5 billion, primarily due to strong sales of its immunology and oncology products [1] - The company is actively pursuing strategic acquisitions to diversify its product portfolio and enhance growth prospects [1] - AbbVie is focusing on research and development to bring new therapies to market, which is expected to drive future revenue growth [1]

Core Insights - The article emphasizes the importance of dividend investing, highlighting that the best dividend stocks not only provide consistent payouts but also increase their dividends over time, benefiting long-term shareholders [1] Group 1: Dividend Growth Leaders - Johnson & Johnson (JNJ) has a 2.54% yield and has increased dividends for 62 consecutive years, supported by a diversified portfolio in healthcare [5][6] - Coca-Cola (KO) boasts a 2.87% yield with 63 years of dividend increases, demonstrating strong operational performance and pricing power [8][9] - Procter & Gamble (PG) leads with 68 consecutive years of dividend increases, offering a 2.96% yield and showcasing operational excellence [11][12] - AbbVie (ABBV) has the fastest dividend growth in this ranking, with a recent 5.5% increase, bringing its yield to 2.94% [15][16] - Realty Income (O) offers a unique monthly dividend structure with a 5.62% yield, supported by a strong rent recapture rate and a long history of dividend increases [18][19] Group 2: Financial Performance - JNJ reported Q3 2025 EPS of $2.80, with revenue of $24.0 billion, and raised its full-year guidance, indicating confidence in growth [6][7] - Coca-Cola's Q3 2025 EPS was $0.86, with revenue of $12.5 billion and a stable operating margin of 32%, reflecting its ability to pass costs to consumers [9][10] - Procter & Gamble's Q1 fiscal 2026 EPS was $1.95, with revenue of $22.4 billion and a free cash flow of $5.4 billion, indicating strong cash generation [12][13] - AbbVie's Q3 2025 EPS was $1.86, with revenue of $15.8 billion, and management raised its EPS guidance for the full year [16][17] - Realty Income's Q3 2025 AFFO reached $1.08 per share, with a full-year guidance increase and a quarterly revenue growth of 10.3% year-over-year [19][20]

Core Viewpoint - AbbVie remains attractively valued despite recent challenges, with potential for market-beating returns over the next five years [2] Valuation Metrics - AbbVie trades at 16.8 times forward earnings, lower than the healthcare sector average of 18.3 and the S&P 500 average of 22.6 [4] - The price/earnings-to-growth (PEG ratio) of 0.43 indicates that AbbVie is undervalued [4] Key Financial Data - Current stock price is $224.14 with a market cap of $398 billion [5] - The stock has a 52-week range of $164.39 to $244.81 and a gross margin of 69.68% [6] Growth Drivers - AbbVie has a diverse product lineup in neuroscience, oncology, and immunology, with Skyrizi and Rinvoq as key growth drivers [7] - These products are approved for multiple indications and will maintain patent exclusivity for at least the next five years [8] Future Prospects - AbbVie is expected to expand its product lineup through new approvals from its extensive pipeline [9] - The company will not face major patent cliffs through the end of the 2020s, supporting consistent revenue and earnings growth [8] Dividend Information - AbbVie is recognized as a Dividend King, having increased its payouts for 54 consecutive years [10] - The company's strong dividend program makes it an attractive option for income-seeking investors [11]

Core Insights - AbbVie is significantly expanding its oncology presence, moving from a two-drug franchise to include solid tumors, with new drugs like Epkinly, Elahere, and Emrelis contributing to over 11% of total revenues in the first nine months of 2025, reflecting a 3% year-over-year growth [1][9] Expansion Strategies - The expansion is driven by both organic and inorganic strategies, with Emrelis being AbbVie's first internally developed solid tumor drug, while Epkinly and Elahere were acquired through collaborations [2] - Sales from newer drugs and rising Venclexta sales have offset the decline in Imbruvica sales due to competition from novel therapies [2] Pipeline Development - AbbVie has a diverse pipeline of new therapies for blood cancers and solid tumors, including antibody-drug conjugates (ADCs), which are seen as a disruptive innovation in cancer treatment [3] - A regulatory filing for the ADC therapy pivekimab sunirine is under FDA review for treating a rare blood cancer, which could add a third ADC to AbbVie's portfolio [4] - The company is also developing Temab-A for metastatic colorectal cancer and other cancers in various stages of clinical trials [4][5] Competitive Landscape - Major competitors in the oncology space include AstraZeneca, Merck, and Pfizer, with AstraZeneca's oncology sales accounting for 43% of total revenues and growing 16% year-over-year [6] - Merck's Keytruda accounted for about 48% of its total revenues, while Pfizer's oncology revenues grew 7%, making up over 27% of its total revenues [7] Financial Performance - AbbVie shares have outperformed the industry year to date, trading at a slight discount with a P/E ratio of 15.87 compared to the industry average of 16.31 [8][11] - EPS estimates for 2025 and 2026 have declined in the past 60 days, indicating potential challenges ahead [13]

Core Insights - AbbVie Inc. (NYSE:ABBV) is recognized as one of the 15 Best Stocks to Buy for the Long Term [1] - HSBC upgraded AbbVie to Buy and raised its price target from $225 to $265, while Piper Sandler reiterated a Buy rating with a price target of $289, indicating a 29.6% upside potential [2] Financial Performance - AbbVie has reported significant sales growth in its top-selling drugs: Skyrizi achieved $4.7 billion in sales with a 46.8% increase, Rinvoq generated $2.18 billion with a 35.3% year-over-year growth, and Humira reached $993 million, reflecting a 55.4% growth from the previous year [3] - The management anticipates further growth, projecting Rinvoq to generate $11 billion in revenues by 2027 and Skyrizi to reach $20 billion, supported by a strong drug portfolio and pipeline expansion through acquisitions [4] Dividend Information - AbbVie raised its quarterly dividend by 5.5% to $1.73 per share, marking the 53rd consecutive year of dividend growth, resulting in an annual payout of $6.92 per share [5]

Group 1 - The healthcare sector, particularly pharmaceutical giants, is being explored for potential investment opportunities due to their underperformance during the recent AI market trends [1] - The focus is on identifying promising under-the-radar stocks that may not yet be recognized by the broader market [1] Group 2 - The analyst has a beneficial long position in ABBV shares, indicating confidence in the company's future performance [2] - The article reflects the analyst's personal opinions and is not influenced by any business relationships with mentioned companies [2]

Group 1 - The healthcare sector, particularly pharmaceutical companies, is being explored for potential investment opportunities due to their underperformance during the recent AI market surge [1] - The focus is on identifying promising under-the-radar stocks that may not yet be recognized by the broader market [1] - The investment strategy emphasizes a balanced approach, combining value stocks with growth opportunities, supported by thorough research and a long-term perspective [1] Group 2 - The analyst has a beneficial long position in ABBV shares, indicating a personal investment interest in the company [2] - The article reflects the analyst's own opinions and is not influenced by any business relationships with mentioned companies [2]